Pluri (4DX) Stock Overview
A biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
4DX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Pluri Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.60 |
| 52 Week High | US$7.32 |
| 52 Week Low | US$3.10 |
| Beta | 1.62 |
| 1 Month Change | 0% |
| 3 Month Change | -10.83% |
| 1 Year Change | 1.45% |
| 3 Year Change | -79.24% |
| 5 Year Change | -86.89% |
| Change since IPO | -76.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4DX | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | 0.7% |
| 1Y | 1.4% | -29.7% | 14.6% |
Return vs Industry: 4DX exceeded the German Biotechs industry which returned -16.6% over the past year.
Return vs Market: 4DX underperformed the German Market which returned 4.2% over the past year.
Price Volatility
| 4DX volatility | |
|---|---|
| 4DX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 4DX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 4DX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 129 | Yaky Yanay | www.pluri-biotech.com |
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company’s development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications.
Pluri Inc. Fundamentals Summary
| 4DX fundamental statistics | |
|---|---|
| Market cap | €24.83m |
| Earnings (TTM) | -€20.13m |
| Revenue (TTM) | €317.54k |
Is 4DX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4DX income statement (TTM) | |
|---|---|
| Revenue | US$341.00k |
| Cost of Revenue | US$9.00k |
| Gross Profit | US$332.00k |
| Other Expenses | US$21.95m |
| Earnings | -US$21.62m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.01 |
| Gross Margin | 97.36% |
| Net Profit Margin | -6,339.59% |
| Debt/Equity Ratio | 1,304.3% |
How did 4DX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/25 12:29 |
| End of Day Share Price | 2024/03/28 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pluri Inc. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Venezia | Alliance Global Partners |
| George Zavoico | B. Riley Securities, Inc. |
| Christian Orquera | First Berlin Equity Research GmbH |